Validated UPLC-MS/MS Method for Determination of Futibatinib and Its Pharmacokinetics in Beagle Dogs

Table 2

Recovery and ME of futibatinib in the beagle dog plasma (n = 6).

Skipped (ng/mL)	Recovery (%)		Matrix effect (%)
	Mean ± SD	RSD (%)	Mean ± SD	RSD (%)
1.0	81.22 ± 4.16	5.12	98.08 ± 5.35	5.46
10	83.95 ± 4.10	4.89	103.21 ± 6.43	6.23
75	85.34 ± 3.61	4.24	101.94 ± 4.26	4.18